Kiniksa Pharmaceuticals (KNSA)
(Delayed Data from NSDQ)
$25.44 USD
-0.28 (-1.09%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $25.44 0.00 (0.00%) 5:04 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Cash flow Statements
Fiscal Year End for Kiniksa Pharmaceuticals, Ltd falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 14.08 | 183.36 | -157.92 | -161.38 | -161.87 |
Depreciation/Amortization & Depletion | 2.34 | 2.40 | 2.36 | 2.41 | 2.07 |
Net Change from Assets/Liabilities | 1.35 | -22.58 | 0.69 | -4.79 | -17.03 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | -4.47 | -157.38 | 28.58 | 27.24 | 18.46 |
Net Cash From Operating Activities | 13.30 | 5.81 | -126.30 | -136.53 | -158.37 |
Property & Equipment | -0.13 | -0.01 | -0.42 | -0.28 | -3.20 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -29.43 | -8.06 | 149.05 | -23.16 | 52.42 |
Other Investing Activities | 0.00 | 0.00 | -20.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -29.56 | -8.08 | 128.64 | -23.44 | 49.21 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 3.70 | 3.42 | 5.89 | 228.22 | 84.23 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -2.21 | -0.90 | 0.00 | -1.14 | -0.12 |
Net Cash from Financing Activities | 1.50 | 2.52 | 5.89 | 227.09 | 84.11 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -14.76 | 0.25 | 8.22 | 67.11 | -25.05 |
Cash at Beginning of Period | 122.72 | 122.47 | 114.25 | 47.14 | 72.19 |
Cash at End of Period | 107.95 | 122.72 | 122.47 | 114.25 | 47.14 |
Diluted Net EPS | 0.20 | 2.60 | -2.30 | -2.61 | -2.99 |
Fiscal Year End for Kiniksa Pharmaceuticals, Ltd falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -21.61 | -17.70 | 14.08 | -11.15 | 2.70 |
Depreciation/Amortization & Depletion | 0.90 | 0.47 | 2.34 | 1.80 | 1.20 |
Net Change from Assets/Liabilities | -1.33 | 8.58 | 1.35 | 5.31 | -5.70 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 31.20 | 12.65 | -4.47 | 13.02 | -6.21 |
Net Cash From Operating Activities | 9.16 | 3.99 | 13.30 | 8.98 | -8.01 |
Property & Equipment | -0.06 | -0.08 | -0.13 | -0.07 | -0.06 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -21.21 | 25.61 | -29.43 | -14.59 | -2.33 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -21.27 | 25.52 | -29.56 | -14.66 | -2.39 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 5.13 | 3.99 | 3.70 | 2.74 | 1.09 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -1.69 | -0.38 | -2.21 | -1.94 | -0.84 |
Net Cash from Financing Activities | 3.44 | 3.61 | 1.50 | 0.80 | 0.25 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -8.68 | 33.12 | -14.76 | -4.89 | -10.15 |
Cash at Beginning of Period | 107.95 | 107.95 | 122.72 | 122.72 | 122.72 |
Cash at End of Period | 99.27 | 141.08 | 107.95 | 117.83 | 112.57 |
Diluted Net EPS | -0.06 | -0.25 | 0.37 | -0.20 | 0.21 |